Reversible ocular myasthenia gravis or mitochondrial myopathy from statins? [15]

Lancet

Volumn 361, Issue 9351, 2003, Pages 85-86

  Engel, W K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CYCLOSPORIN A; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; NICOTINIC ACID; PREDNISOLONE; PYRIDOSTIGMINE; PYRROLE; STATIN;

DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE DURATION; DRUG INDICATION; HUMAN; LETTER; MITOCHONDRIAL MYOPATHY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PTOSIS;

EID: 0037417477     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12152-6     Document Type: Letter

References (5)

1. Parmar B., Francis P.J., Ragge N.K. Statins, fibrates, and ocular myasthenia. Lancet. 360:2002;717.
2. Warmolts J.R., Engel W.K., Whitaker J.N. Alternate-day prednisone in a patient with myasthenia gravis. Lancet. 2:1970;1198-1199.
3. Engel WK. "Ragged-red fibers" in ophthalmoplegia syndromes and their differential diagnosis. Abstracts of the 2nd International Congress on Muscle Diseases; Perth, Australia, 1971. Excerpta Medica International Congress Series No 237. Amsterdam: Excerpta Medica, 1971: 28.
4. Bernini F., Poli A., Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther. 15:2001;211-218.
5. Ucar M., Mjorndal T., Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 22:2000;441-457.